New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- DNA 2.0
- 1140 O'Brien Drive, Suite A
- Menlo Park CA, 94025
- UNITED STATES
Founded in early 2003, DNA2.0 is a privately-held, leading synthetic biology company, headquartered in Menlo Park, CA. It is the largest US provider of synthetic genes, with a global customer base comprised of academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries.